Neogen Corporation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Neogen Corporation (NEOG) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.00 million shares for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-30
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-02-28 was 1.66M shares, a 3146.50% increase year-over-year.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-08-31 was 661.00K shares.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-02-28 was 51.23K shares.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-08-31 was 45.00K shares.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2026 was 1.00M shares, a 900.00% increase from fiscal 2025.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 100.00K shares, a 66.67% decline from fiscal 2024.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 300.00K shares, a 103.15% increase from fiscal 2023.
- Neogen Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 147.67K shares, a 61.44% decline from fiscal 2022.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | 1.00M shares 10-K · filed 2026-07-30 | |||||
| 2026-02-28 | 1.66M shares 10-Q · filed 2026-04-09 | 4.21M shares 10-Q · filed 2026-04-09 | ||||
| 2025-11-30 | 3.06M shares 10-Q · filed 2026-01-08 | |||||
| 2025-08-31 | 661.00K shares 10-Q · filed 2025-10-09 | |||||
| 2025-05-31 | 100.00K shares 10-K · filed 2026-07-30 | 120.74K shares 10-K · filed 2025-07-30 | ||||
| 2025-02-28 | 51.23K shares 10-Q · filed 2026-04-09 | 223.81K shares 10-Q · filed 2026-04-09 | ||||
| 2024-05-31 | 300.00K shares 10-K · filed 2026-07-30 | 332.02K shares 10-K · filed 2024-07-30 | ||||
| 2023-08-31 | 45.00K shares 10-Q · filed 2024-10-10 | |||||
| 2023-05-31 | 147.67K shares 10-K · filed 2025-07-30 | 148.00K shares 10-K · filed 2023-08-15 | ||||
| 2022-05-31 | 383.00K shares 10-K · filed 2023-08-15 | |||||
| 2021-05-31 | 0.00 shares 10-K · filed 2023-08-15 | |||||
| 2020-05-31 | 28.00K shares 10-K · filed 2020-07-30 | 56.00K shares 10-K · filed 2022-07-27 | ||||
| 2019-05-31 | 5.00K shares 10-K · filed 2020-07-30 | 10.00K shares 10-K · filed 2021-07-30 | 0.00 shares 10-K · filed 2019-07-30 | |||
| 2018-05-31 | 0.00 shares 10-K · filed 2019-07-30 | |||||
| 2017-05-31 | 0.00 shares 10-K · filed 2019-07-30 | |||||
| 2016-05-31 | 0.00 shares 10-K · filed 2018-07-27 | |||||
| 2015-05-31 | 0.00 shares 10-K · filed 2017-07-28 | |||||
| 2014-05-31 | 48.72K shares 10-K · filed 2016-07-29 | |||||
| 2013-05-31 | 88.91K shares 10-K · filed 2015-07-30 | 0.00 shares 10-K · filed 2013-07-30 | ||||
| 2012-05-31 | 78.45K shares 10-K · filed 2014-07-30 | 52.30K shares 10-K · filed 2012-07-30 | ||||
| 2011-05-31 | 12.00K shares 10-K · filed 2013-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |